Skip to main content
. Author manuscript; available in PMC: 2007 Jan 15.
Published in final edited form as: Clin Cancer Res. 2006 Jan 15;12(2):600–607. doi: 10.1158/1078-0432.CCR-05-1325

Fig. 1.

Fig. 1

A, Cetuximab does not inhibit the proliferation of ATC cell line ARO. ARO cells were incubated with 0.5 g/mL of cetuximab for 72 hours. The degree of proliferation was then measured with an MTT assay. B, Cetuximab enhances the anti-proliferative effects of irinotecan. ARO cells were incubated with various concentrations of irinotecan with and without 0.5 g/mL of cetuximab for 72 hours. The degree of proliferation was then measured with an MTT assay. C, Cetuximab does not induce the apoptosis of ATC cell line ARO. ARO cells were incubated with 1 g/mL of cetuximab for 48 hours. The degree of apoptosis was then measured using a flow-cytometry based assay on Propidium Iodide stained cells. D, Cetuximab enhances the proapoptotic effects of irinotecan. The ARO cells were treated with various concentrations of irinotecan for 24 hours. Cetuximab was then added to a final concentration of 1 g/mL and the cells were incubated in the presence of both cetuximab and irinotecan for additional 48 hours.